HYPB CRISPR Activation Plasmid (h): sc-402789-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HYPB CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- HYPB CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by HYPB CRISPR Activation Plasmid (h) and HYPB CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SETD2 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HYPB CRISPR Activation Plasmid (h) | sc-402789-ACT | 20 µg | $397.00 |
SETD2 (HYPB) encodes a SET domain–containing histone methyltransferase that catalyzes trimethylation of histone H3 lysine 36 (H3K36me3) across actively transcribed gene bodies. This chromatin mark coordinates transcriptional elongation with pre-mRNA splicing, DNA damage repair, and maintenance of genome stability through recruitment of H3K36me3 “reader” complexes. SETD2 activity also influences DNA mismatch repair and homologous recombination pathways, linking epigenetic regulation to replication fidelity. Disruption or dysregulation of SETD2-dependent H3K36 methylation is associated with altered chromatin states, transcriptional misregulation, and genome instability observed across multiple cancer and developmental disease contexts.
HYPB CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SETD2 expression without altering the underlying DNA sequence.
HYPB CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SETD2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SETD2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous HYPB expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SETD2 locus and enabling the study of HYPB-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of HYPB pathway restoration in tumor cells with silenced or reduced SETD2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.